Prometheus MedTech.AI at NeoHeart 2025: A Milestone Toward U.S. Market Entry

Prometheus MedTech.AI has taken a major step toward its U.S. market entry and future FDA certification by participating in NeoHeart 2025 (San Diego, July 29–August 1) — the leading international conference in neonatal and pediatric cardiology.

Our Chief Medical Officer and Founder, Wiktor Strzelczyk, joined more than 120 world-class speakers and hundreds of clinicians at this landmark 10th edition. By engaging directly with top experts and high-volume clinical centers in the U.S., we strengthened existing partnerships, opened doors to new research collaborations, and validated that our AI technology meets the expectations of frontline healthcare professionals.

Why this matters

• Confirmed interest from U.S. hospitals to explore research partnerships.
• Validation that our solution integrates seamlessly into real-world, high-volume clinical settings.
• Insights into U.S. healthcare and regulatory requirements to guide our FDA pathway.

Beyond technology: collaboration at the core

At Prometheus, we focus on the early detection of congenital heart defects (CHDs) in both fetuses (18–26 weeks) and newborns. Our solutions are designed to support — not replace — clinicians, ensuring that technology amplifies medical expertise.

A powerful theme echoed at NeoHeart by Dr. Steven Abman reminded us: true progress in medicine comes when professionals collaborate openly across systems, specialties, and borders, with patient well-being at the center. This philosophy defines how we build and scale Ultra Echo Scan.

Looking ahead

We return from San Diego with stronger momentum for our U.S. strategy and are already preparing for NeoHeart 2026 in London — continuing our journey to transform neonatal and pediatric cardiac care worldwide.

Follow Prometheus MedTech.AI to track our progress in tackling the global challenge of low CHD detection rates in children.